Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

0.3971 -0.0050 (-1.24%)
Streaming Delayed Price Updated: 3:44 PM EDT, Aug 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 291,895
Open 0.4150
Bid (Size) 0.3970 (100)
Ask (Size) 0.4071 (200)
Prev. Close 0.4021
Today's Range 0.3850 - 0.4200
52wk Range 0.3252 - 13.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire

Performance

YTD
-67.5%
-67.5%
1 Month
-43.6%
-43.6%
3 Month
-76.4%
-76.4%
6 Month
-62.9%
-62.9%
1 Year
-94.6%
-94.6%

More News

Read More
News headline image
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Q2 Virtual Investor Summit Presentations Now Available On Demand
From Investor Summit Group
Via ACCESS Newswire
News headline image
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of $3.2 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
News headline image
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
What's Going On With bioAffinity Technologies Stock Wednesday? ↗
Via Benzinga
News headline image
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
From bioAffinity Technologies, Inc.
Via Business Wire
What's going on in today's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is bioAffinity Technologies, Inc. - Common Stock publicly traded?
Yes, bioAffinity Technologies, Inc. - Common Stock is publicly traded.
What exchange does bioAffinity Technologies, Inc. - Common Stock trade on?
bioAffinity Technologies, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for bioAffinity Technologies, Inc. - Common Stock?
The ticker symbol for bioAffinity Technologies, Inc. - Common Stock is BIAF on the Nasdaq Stock Market
What is the current price of bioAffinity Technologies, Inc. - Common Stock?
The current price of bioAffinity Technologies, Inc. - Common Stock is 0.3971
When was bioAffinity Technologies, Inc. - Common Stock last traded?
The last trade of bioAffinity Technologies, Inc. - Common Stock was at 08/17/26 03:44 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.